What is Xilis?
Xilis operates at the intersection of biotechnology and artificial intelligence, providing a sophisticated platform that enables oncologists to make data-driven treatment decisions. By utilizing its proprietary MicroOrganoSphere (MOS) technology, the company creates miniature patient tumors that accurately replicate the heterogeneity and microenvironment of actual human cancers. This scalable solution not only assists clinicians in selecting the most effective therapies but also serves as a critical tool for pharmaceutical companies engaged in drug discovery and clinical trial patient selection. By bridging the gap between preclinical modeling and clinical outcomes, Xilis is positioning itself as a foundational player in the future of personalized medicine.
How much funding has Xilis raised?
Xilis has raised a total of $92M across 2 funding rounds:
Angel/Seed
$3M
Series A
$89M
Angel/Seed (2019): $3M with participation from Felicis Ventures, Guardant Health, Pear, Liquid 2 Ventures, and 8VC
Series A (2022): $89M led by GV, Life Sciences Partners, Alexandria Venture Investments, Pear Ventures, EQT Life Sciences, Mubadala Capital Management, Catalio Capital Management, and FPV Ventures
Key Investors in Xilis
Pear VC
Pear VC specializes in pre-seed and seed investments, partnering with founders at the earliest stages to develop innovative companies with a focus on long-term value creation.
8VC
8VC is a venture capital firm that focuses on building and scaling technology companies, often providing strategic guidance to startups in the government and enterprise sectors.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing, focusing on breakthrough biomedical technology companies across private and public markets.
What's next for Xilis?
With the recent capital injection, Xilis is well-positioned to accelerate the clinical validation of its Xilis Response Score and expand its high-throughput preclinical modeling capabilities. The strategic focus will likely shift toward scaling operations to meet the demands of global pharmaceutical partners and integrating its AI-driven algorithms into broader clinical workflows. As the company transitions from early-stage development to a more mature commercial phase, the emphasis will remain on enhancing the accuracy of tumor microenvironment analysis, thereby solidifying its role as an essential partner in the development of next-generation cancer therapeutics.
See full Xilis company page
